| Ytd | 87.95% | |
| 1y | 348.86% |
| Open | 10.15 | Prev Close | 10.31 | Low | 9.60 | High | 10.29 | Mkt Cap | 699.80M |
| Vol | 1.82M | Avg Vol | 1.36M | EPS | -0.92 | P/E | N/A | Forward P/E | -3.96 |
| Beta | 0.10 | Short Ratio | 2.94 | Inst. Own | 17.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.24 | 200-d Avg | 6.61 | 1yr Est | 7.00 |
IMMX News
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyl
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Chec
B of A Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy a
Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028.
The gross proceeds to Immix from the offering, before deducting the underwriting discounts, commissi
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)
HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and ra
Citizens analyst Reni J. Benjamin reiterates Immix Biopharma (NASDAQ:IMMX) with a Market Outperfo
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy a
Immix Biopharma (NASDAQ:IMMX) reported quarterly losses of $(0.28) per share which missed the analys
Morgan Stanley analyst Judah Frommer initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a O
Wall Street analysts make changes to top stocks. Check our analyst ratings page for all updates. VAL
Wall Street analysts upgraded and initiated coverage on top stocks, including Redwire, Zions Bancorp
Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst r
Citizens analyst Reni Benjamin initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Market
Mizuho analyst Graig Suvannavejh initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Outpe
Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "I
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new she
OKLO: 24% | Shares of OKLO and nuclear-linked stocks are trading higher amid report that President T
On Wednesday, 283 companies set new 52-week lows.
On Monday, 160 companies hit new 52-week lows.
Friday's session saw 236 companies set new 52-week lows.
On Tuesday, 85 stocks hit new 52-week lows.
On Thursday, 111 stocks hit new 52-week lows.
On Wednesday, 53 companies reached new 52-week lows.
On Tuesday, 120 companies set new 52-week lows.
During Tuesday's session, 78 companies made new 52-week lows.
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 12
During Wednesday's trading, 517 companies set new 52-week lows.
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday afte
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares jumped 360.8% to $9.86 after the company annou
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Monday, 721 companies achieved new lows for the year.
Tuesday's session saw 729 companies set new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
Wednesday's session saw 107 companies set new 52-week lows.